Browsing Category
Pharma Industry News
4720 posts
Business-News-Today.com section for global pharma industry news, Indian pharma sector latest news, pharma sector news today, pharmaceuticals industry news.
Clinuvel Pharmaceuticals (ASX: CUV; Nasdaq: CUVL) reorganises around U.S. markets after Nasdaq debut
Clinuvel Pharmaceuticals is aligning its organisation with an increasingly U.S.-centred commercial and clinical strategy, but the value of the reset will depend on measurable progress rather than greater Nasdaq visibility alone.
Picard Medical can lift PMI’s quoted price 50-fold, but can it repair the balance sheet?
Picard Medical’s share consolidation could strengthen its quoted price and preserve market access, but investors still need evidence of improved equity, liquidity and commercial scale.
Dyne Therapeutics (NASDAQ: DYN) slides as $375m stock sale resets valuation
Dyne Therapeutics strengthens launch funding, but its discounted $375 million share sale tests whether regulatory progress can outrun dilution pressure.
Palvella Therapeutics (NASDAQ: PVLA) rebounds 15% as investors reassess FDA path
Palvella Therapeutics is recovering from a sharp selloff as investors separate its advancing QTORIN rolling application from uncertainty surrounding a second indication.
Nextpower expands beyond solar trackers after closing Prevalon Energy transaction
Nextpower has converted its battery storage strategy from an acquisition proposal into an operating business. Prevalon adds deployed systems, software and data centre contracts, but integration and profitable growth now become the decisive tests.
Telix Pharmaceuticals (ASX: TLX) revenue tops $247m as pipeline spending rises
Telix Pharmaceuticals revenue is accelerating, but rising R&D spending and FDA decisions will determine whether ASX: TLX can regain its premium.
Mesoblast (ASX: MSB; Nasdaq: MESO) CEO invests A$2.73m as Ryoncil growth shifts focus to execution
Mesoblast Chief Executive Silviu Itescu has paid A$2.73 million to increase his ownership, adding an alignment signal as Ryoncil sales and late-stage programs reshape the company.
Syntara’s (ASX: SNT) AZALOX trial clears first safety hurdle and advances to final 200 mg cohort
Syntara Limited has advanced its AZALOX study into the final Phase 1b cohort after the first patients completed treatment without dose-limiting toxicities, keeping a preliminary Q4 2026 data release on track.
Thalia Therapeutics (AIM: THAT) completes Sanmirna acquisition to add Phase 1 AML asset
Thalia Therapeutics has completed its acquisition of Sanmirna Therapeutics, adding the Phase 1 miRisten programme for relapsed or refractory acute myeloid leukaemia. The deal accelerates Thalia’s transition into clinical-stage RNA therapeutics, but more than doubles its share count and leaves future value dependent on safety data, early biological evidence and further financing.
Dimerix (ASX: DXB) buys Phase 2-ready DMX-652 in deal worth up to $292m
Dimerix buys Phase 2-ready DMX-652 for US$5 million upfront, widening its kidney pipeline while taking on milestones, royalties and execution risk ahead.